• No results found

Scaled B ay es factor

N/A
N/A
Info
Downloaden
Protected

Academic year: 2021

Share "Scaled B ay es factor"

Copied!
8
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Download het nu ( 8 pagina )

Hele tekst

(1)

CAP256 serum with autologous CAP256 reference sequence

Scaled B ay es factor

v

MPER

CAP256 serum with CAP210 reference sequence

Scaled B ay es factor

v

MPER

CAP256 serum with CAP45 reference sequence

Scaled B ay es factor

v

MPER

747

186 0.80

titer 1.00

535 0.80

347 0.79

143 0.75

375 0.77

621 0.78

24 0.89

460 0.80

164

0.86

490 440 0.80

0.86

1.00

152

671 0.81 1.00

1.00 580

1.00 0.82 32

0.99 2

1.00 0.83

744

1.00

29

1.00

1.00

1.00 1.00

187 1.00 271

0.81 0.99

1.00 739

1.00 0.78 5

0.81 702 0.91 0.77

1.00

1.00

1.00

166 1.00

234 1.00 1.00

0.85

1.00

201

1.00 0.80

0.80

7 0.84 0.75

1.00

169 1.00

A

B

C

D E

Figure S1

(2)

CAP8 serum with ConC reference sequence

Scaled B ay es factor

v

MPER

CAP8 serum with Q23 reference sequence

Scaled B ay es factor

v

MPER

CAP8 serum with TRO reference sequence

Scaled B ay es factor

v

MPER

683

titer

0.89

740 0.84

0.96

535

0.90

687 0.76

0.83

316

0.83

335 0.88 0.80

626

0.82 295

0.77 27

0.79

0.76

24 0.95 293

0.77 619

0.79

169

1.00 0.76

674

0.75

440 0.76 0.77

565 0.87

580 0.93 0.77

0.97

0.88 684

0.80 0.96

0.88

A

B

C

D E

Figure S2

(3)

CAP257 serum with ConC reference sequence

Scaled B ay es factor

v

MPER

CAP257 serum with Q842 reference sequence

Scaled B ay es factor

v

MPER

317

240 0.75

titer

815 0.78

0.77 134

347 0.87 1.00 0.75

567 0.80

92 0.82 0.79

659

0.91

655 0.75

404 0.79

0.90

705 0.75 640 829 0.83

0.78 580

496 0.85 0.76 32

0.80 4

0.76 460

0.78 0.81 406

0.75 68

106 0.99

0.77 2

0.82 0.75

0.76

166 0.83

856

0.89 0.76

752 0.76

816

0.80 0.76 0.83

0.77

702 0.84

354 0.85

453 0.86 747

0.87 1.00

1.00

1.00

728

0.83

0.76 244

0.75 0.79

281 0.83

288 0.98

0.76

0.77

139 0.97

0.75

20 0.80

626 0.78

A

B

C D

Figure S3

(4)

CAP255 serum with autologous CAP255 reference sequence

Scaled B ay es factor

v

MPER

CAP255 serum with TRO reference sequence

Scaled B ay es factor

v

MPER

CAP255 serum with Q23 reference sequence

Scaled B ay es factor

v

MPER

A

B

C

Figure S4

(5)

CAP177 serum with ConC reference sequence

Scaled B ay es factor

v

MPER

CAP177 serum with Q23 reference sequence

Scaled B ay es factor

v

MPER

CAP177 serum with TRO reference sequence

Scaled B ay es factor

v

MPER

683

titer 0.85

332 0.98

0.80 740

0.76 0.90

334 0.83

393 0.75

337 0.75 836

0.78 684

0.76 0.76 425

0.76 0.78

323 0.98

0.81 624 169

0.78 182

0.83 731

0.88

A

B

C

D

Figure S5

(6)

CAP206 serum with ZM197 reference sequence

Scaled B ay es factor

v

MPER

CAP206 serum with autologous CAP206 reference sequence

Scaled B ay es factor

v

MPER

CAP206 serum with CAP45 reference sequence

Scaled B ay es factor

v

MPER

CAP206 serum with Q23 reference sequence

Scaled B ay es factor

v

MPER

CAP206 serum with TRO reference sequence

Scaled B ay es factor

v

MPER

CAP206 serum with COT6 reference sequence

Scaled B ay es factor

v

MPER

740

184 0.88

titer 0.92

818 0.77 683 0.78

0.99

655 0.75 0.86

448 0.84

A

B

C

D

E

F

G

Figure S6

(7)

CAP248 serum with ConC reference sequence

0

Scaled B ay es factor

v

MPER

CAP248 serum with CAP45 reference sequence

0

Scaled B ay es factor

v

MPER

CAP248 serum with DU156 reference sequence

0

Scaled B ay es factor

v

MPER

A

B

C

D

703

titer 0.92

238 0.75

362

0.95

0.88

0.76 674

655 0.80

659 0.84

0.75

336 0.79 513 0.83 676

0.77 340

0.75 346

0.89 746

0.75

169 0.76

0.87 651

0.78

12 0.98

0.94

65 1.00 152

1.00

0.86

0.98 0.90

762 0.75 0.92

0.90

0.99

0.97

839 0.79

0.78

0.91

0.78

85 0.86

0.76

Figure S7

(8)

−20 −10 0 10 20 30

− 20 − 10 0 10 20 30

CAP256 serum with ConC reference sequence

Scaled Bayes factors obtained with median titers

Scaled Ba yes f actors obtained with reconstr ucted titers

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

● ●

●

●

●

●

●

● ●

●

●

● ●

●

● ●

●

●

●

●

● ●

● ●

●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

● ● ●

●

●

●

● ● ● ●

●

●

●

●

●

●

●

● ●

●

●

● ●

● ●

●

● ●●

●

● ●

●

●

●

●

●

●

●

●

●

● ●

●

● ●

●

●

●

●

●

●

●

●

●

● ●

●

● ●

●

●

●

●

● ●

●

●

● ●

● ●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ● ● ●

●

●

● ● ● ● ●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

● ●●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●●

●

●

●

●

● ● ●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

● ●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

●

●

●

●

● ● ●

●

● ●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

● ●

●

●

●

● ●

●

●

●

●

●

●

●

● ● ●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

● ●

●

●

●

● ● ●

●

●

●

●

●

●

●

●

●●

●

●

● ● ●

●

● ●

●

●●

●

● ●

●

●

●

●

● ●

●

●●

●

●

●●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

● ●

● ●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

● ●

●

●

●

●

●

● ● ● ● ● ●

●

●

●

●

●

●

● ●

●●

●

●

● ●

● ●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

● ●

●

● ● ●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

● ● ●

●

●

●

●

●

●

●

●

●

●

●

●●

● ●

●

●

● ●

● ●

● ●

●

●

●

● ●

●

●

●

●

●

●

● ●

●

●

●

●

● ●

●

●

●

●

● ●

●

●

●

●

●

●●

●

●

●

●

●

●

●

● ●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

● ●

●

● ●

●

●

●

●

●

●

●

● ●

●

●

●●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●●

●

● ●

●

● ●

●

●

● ● ●

●

●

●

●

●

●

● ●

● ●

●● ●

●

●●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

●

● ●

●

●

●

●

● ●

●●

●

●

●

●

●

● ●

r = 0.928

Figure S8

Referenties

Download het nu ( PDF - 8 pagina - 1.41 MB )

GERELATEERDE DOCUMENTEN

De verkeersonveiligheid in de provincie Noord-Brabant IX E

Behalve bij strengen waarvan een gedeelte openstaat voor gemengd verkeer bestaat er geen duidelijKe relatie tussen het aantal ongevallen op de streng en de

De verkeersonveiligheid in de provincie Noord-Brabant X

Hoewel de verkeersonveiligheid in Noord-Brabant groot is in vergelijking met andere provincies, kan deze provincie niet worden bestempeld als de meest onveilige

Application of membrane technology for purifying tyre derived oil

The aim of this study is to investigate the purification (recovery of limonene and reduction of benzothiazole) of TDO using a novel green separation technology,

. RESULT.ATE EN GEVOLGrrREKKINGS • I~. ·vraelys:

·genoemne rede ·word weerspreek deur di~ reaksie van die proefpersone op· hierdie vraag.. Die probleem

Leapfrogging to renewable energy : the opportunity for unmet electricity markets

The key driving factors of leapfrogging conventional energy to renewable energy for electricity generation in the unmet electricity market include: the global goals of a

Archeologische prospectie Neerpelt, Kievitstraat 11 - 13

Lommel Zanden die zijn aangetroffen bestaan uit lichtgeel matig grof zwak siltig (zwak lemig) zand en die van de Formatie van Wildert zijn lichtgeel tot oranjegeel, zeer fijn,

publieksversie

Dementie komt vaak voor bij ouderen, maar ook jonge mensen kunnen dementie krijgen.. Er zijn veel hersenziektes die

Positional in-match running demands of university rugby players in South Africa

(2013) and Tee and Coopoo (2015) reported no significant differences between the two playing positions. Table 2 presents the in-match running demands variables used in the